Menu Search
Equities

Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd

GU5:STU

Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd

Actions
  • Price (EUR)2.16
  • Today's Change0.04 / 1.89%
  • Shares traded0.00
  • 1 Year change-12.90%
  • Beta--
Data delayed at least 15 minutes, as of Nov 05 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd i is engaged in the pharmaceutical and healthcare industry. The Company's segments are Great Southern TCM, Great Commerce, Great Health and Great Medical Care. The Company's Great South TCM includes research, development, manufacturing and sales for Chinese and western medicine, chemical raw medicine, natural drug, biological medicine and intermediates of chemical raw medicine. The Company's Great Health segment includes the research, development, manufacturing and sales of beverages, foods, health products and other products. The Company's Great Commerce segment includes wholesale, retail, import and export for western medicine, Chinese medicine and medical apparatus and instruments. The Great Medical segment is engaged in medical services, traditional Chinese medicine health preservation, modern pension and medical equipment industry.

  • Revenue in HKD (TTM)83.63bn
  • Net income in HKD3.75bn
  • Incorporated1997
  • Employees28.05k
  • Location
    Guangzhou Baiyunshan Pharmaceutical Holdings Co LtdNo. 45 Shamian North StreetLiwan DistrictGUANGZHOU 510130ChinaCHN
  • Phone+86 2 066281218
  • Fax+86 2 066281229
  • Websitehttp://www.gybys.com.cn/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.